CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 51 enrolled
Drug / intervention
Elotuzumab +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01632150
NCT01632150Phase 2Completed
CompareCT.gov

Phase 2a Single-Arm Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma

Bristol-Myers Squibb·interventional·Posted Jul 2, 2012·Updated Apr 14, 2017

In Brief

A Phase 2 clinical trial evaluating Elotuzumab, Thalidomide, and 2 other interventions for Relapsed and/or Refractory Multiple Myeloma. Completed, enrolled 51 participants across 10 sites.

Detailed Summary

The purpose of this study is to determine the safety and tolerability of elotuzumab administered in combination with thalidomide and dexamethasone in the treatment of relapsed and/or refractory multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed and/or Refractory Multiple Myeloma
CountriesSpain
CollaboratorsAbbVie

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 2, 2012
Enrollment StartMay 1, 2012
Primary CompletionOct 1, 2013
Study CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 14 years ago

Interventions

Elotuzumabbiological

Powder for solution, 400-mg vials, for infusion

Thalidomidebiological

50-mg capsules administered orally

Dexamethasonebiological

2- and 4-mg tablets (and various other strengths, as needed) administered orally and in 4- and 8-mg/mL (and various other strengths, as needed) solutions for intravenous administration

Cyclophosphamidebiological

50-mg tablets administered orally